Granules India may rise on licence for COVID-19 drug
New Update
BY A STAFF REPORTER:-
Shares of Granules India are likely to gain today as the company received a licence to make and market COVID-19 drug 2-Deoxy-D-Glucose, also known as 2-DG.
The drug, developed by Defence Research and Development Organisation in collaboration with Dr Reddy's Laboratories, has already received a nod from the Drug Controller General of India for emergency use.
The licence to market the COVID-19 drug will likely improve Granules India's revenue visibility. A few other companies, including Bajaj Healthcare, Shilpa Medicare and Laurus Labs have also signed the licensing agreement for the drug.
Shares of Granules India closed 0.3% lower at 343.80 rupees on Thursday.
/ )
/anm-english/media/post_banners/lkZBiDUsHMrJqGAKfrsT.jpg)
/anm-english/media/agency_attachments/AtBG5e3MoE629QYzhZen.png)
/anm-english/media/post_attachments/3CHUMKF1xuuekeLB6McV.jpeg "publive-image")